Compositions for treatment of psoriasis

Patent metadata

Field	Value
Publication number	US-2024226126-A1
Application number	US-202218568162-A
Country	US
Kind code	A1
Filing date	Jun 15, 2022
Priority date	Jun 16, 2021
Publication date	Jul 11, 2024
Grant date	—

Abstract

Methods of treatment for psoriasis, and compositions for use in such methods are provided, utilizing repositioned drugs identified as anti-psoriasis agents.

First claim

1 . A method of treating psoriasis in a subject, the method comprising:
administering to the subject an effective dose of a compound of Table 1 for duration and periodicity sufficient to reduce the symptoms of psoriasis.

2 . The method of claim 1 , wherein the anti-psoriasis agent is selected from quinostatin

or a derivative thereof; bromocriptine

or a derivative thereof; trifluoperazine

or a derivative thereof; sirolimus

or a derivative thereof; 0297417-0002B

or a derivative thereof; 0198306-0000, PD-198306

or a derivative thereof; PHA-00665752

or a derivative thereof; PNU-0230031 [267429-39-0]

or a derivative thereof; AG-012559 [369370-06-9]

or a derivative thereof; etoposide

or a derivative thereof; or ethacrynic acid

or a derivative thereof.

3 - 12 . (canceled)

13 . The method of claim 2 , wherein the administration is systemic.

14 . The method of claim 2 , wherein the administration is topical.

15 . The method of claim 2 , wherein dose is administered to the subject upon a flare of psoriasis.

16 . The method of claim 2 , wherein the psoriasis is chronic psoriasis.

17 . The method of claim 2 , wherein the psoriasis is plaque psoriasis.

18 . A composition in a unit dose formulation of an anti-psoriasis agent of Table 1, suitable for use in the methods of claim 2 .

19 . The composition of claim 18 , wherein the anti-psoriasis agent is quinostatin

or a derivative thereof.

20 . The composition of claim 18 , wherein the anti-psoriasis agent is bromocriptine

or a derivative thereof.

21 . The composition of claim 18 , wherein the anti-psoriasis agent is trifluoperazine

or a derivative thereof.

22 . The composition of claim 18 , wherein the anti-psoriasis agent is sirolimus

or a derivative thereof.

23 . The composition of claim 18 , wherein the anti-psoriasis agent is 0297417-0002B

or a derivative thereof.

24 . The composition of claim 18 , wherein the anti-psoriasis agent is 0198306-0000, PD-198306

or a derivative thereof.

25 . The composition of claim 18 , wherein the anti-psoriasis agent is PHA-00665752

or a derivative thereof.

26 . The composition of claim 18 , wherein the anti-psoriasis agent is PNU-0230031 [267429-39-0]

or a derivative thereof.

27 . The composition of claim 18 , wherein the anti-psoriasis agent is AG-012559 [369370-06-9]

or a derivative thereof.

28 . The composition of claim 18 , wherein the anti-psoriasis agent is etoposide

or a derivative thereof.

29 . The composition of claim 18 , wherein the anti-psoriasis agent is ethacrynic acid

or a derivative thereof.

30 . The composition of claim 18 , wherein the anti-psoriasis agent is the sole active agent.

31 . The composition of claim 18 , further comprising a second therapeutic agent for treatment of psoriasis.

32 - 33 . (canceled)

Assignees

• Univ Leland Stanford Junior
• Us Gov Veterans Affairs

Inventors

• Marinkovich M Peter
• Butte Atul Janardhan
• Nasrallah Mazen
• Winge Marten Cg

Classifications

• A61K31/5415

  ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/48 Primary

  Ergoline derivatives, e.g. lysergic acid, ergotamine · CPC title

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61K31/436

  the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title